ERBB2 and non-small cell lung carcinoma: Recently, in August 2022, trastuzumab deruxtecan was approved by Food and Drug Administration (FDA) for previously treated human epidermal growth factor receptor 2 (HER2) mutant NSCLC, based on a phase 2 study showing improved outcomes.